Nexstim Plc · OMXHEX:NXTMH
Nexstim — Nexstim Corporate Presentation Webinar 2021
18 slides from Nexstim's conference presentation, Mar 16, 2021
Slide 1: Nexstim. Personalised depression treatment.
Nexstim. Personalised depression treatment. Mikko Karvinen| CEO | Nexstim Plc Joonas Juokslahti| CFO | Nexstim Plc Nexstim Plc Corporate Presentation, Webinar, 16 March 2021 Nexstim Plc
Slide 2: Important Information
Important Information This document and the information contained herein are being presented by Nexstim Oyj other than the date of this presentation. Nothing contained herein is, or should be relied upon (“Nexstim” or the “Company”). In connection with any presentation or review of this document, as
Slide 3: Table of Contents
Table of Contents • Overview • Therapeutic ‒ Major Depressive Disorder (MDD) ‒ Chronic Neuropathic Pain • Diagnostic ‒ Pre-surgical Mapping • Business Update & Key Financials Nexstim Plc Public Presentation 3
Slide 4: Nexstim has a unique proprietary neuronavigated TMS technology
Nexstim has a unique proprietary neuronavigated TMS technology that delivers best in class mapping and treatment for patients with brain diseases and disorders. We are well positioned to a disruptive shift in depression treatment and therapy delivery. With improving economics, driven by record reven
Slide 5: Personalised Transcranial Magnetic Stimulation (TMS) Overview
Personalised Transcranial Magnetic Stimulation (TMS) Overview SmartFocus® Technology with a Highly Sophisticated 3D Navigation • Commercial-stage med tech company with a unique, proprietary Unique & Proprietary navigated neuro-stimulation technology for diagnostic and Technology therapeutic applicat
Slide 6: Nexstim SmartFocus TMS in Brain Therapy
Nexstim SmartFocus® TMS in Brain Therapy Smart, focused and drug-free Nexstim Plc Public Presentation 6
Slide 7: NBT for Depression
NBT® for Depression Therapeutic Nexstim depression business opportunity Market size estimate2 (patients) • Major depressive disorder affects 2-5% of the population in People affected by MDD globally developed countries1 216m Patients not responding to medicines • Existing psychotherapy and pharmacol
Slide 8: Promising Clinical Outcomes
Promising Clinical Outcomes Therapeutic Patients completing SmartFocus® rTMS Treatment of MDD • First 159 patients in Nexstim’s patient registry have completed SmartFocus® rTMS therapy for treatment of MDD at clinical sites in the US • 47% of the patients completing the treatment achieved clinical r
Slide 9: NBT for Chronic Neuropathic Pain
NBT® for Chronic Neuropathic Pain Therapeutic Nexstim neuropathic pain business opportunity Market size of estimate2 People affected by chronic • There are about 10 million addressable neuropathic pain neuropathic pain annually 285m patients in the US and Europe1 Patients not responding to medicines
Slide 10: Nexstim SmartFocus TMS in Diagnostics
Nexstim SmartFocus® TMS in Diagnostics Proprietary technology enabling substantial increase in progression- free survival in brain cancer surgery, commercially validated Nexstim Plc Public Presentation 10
Slide 11: NBS for Pre-surgical Mapping (Diagnostic)
NBS for Pre-surgical Mapping (Diagnostic) Diagnostic Only available technology on the market today NBS Significantly Improves Clinical Outcomes in World-leading Centers Rely on Nexstim‘s Pre-surgical Neurosurgery Mapping Technology NBS Selected institutions out of the 180 ones currently NBS helps su
Slide 12: Nexstim Business Update & Key Financials
Nexstim Business Update & Key Financials Nexstim Plc Public Presentation 12
Slide 13: Nexstim Business Update 2020
Nexstim Business Update 2020 Business Operations • Focused in minimizing the effect of COVID-19 pandemic as well as on generating profitable revenue growth • Considering the difficult business environment, excellent progress with ‒ 13 new NBS Systems sold (6 in the US and 7 in Europe & ROW) ‒ Total
Slide 14: NBT / NBS Revenue – Existing Business
NBT® / NBS Revenue – Existing Business Business Operations Cumulative YTD Total Revenue 2018-2020 4 500 000 € • Steadily growing business, showing all time high 4 000 000 € figures in FY2020 3 500 000 € 3 000 000 € • Annual average therapy revenue per system was 2 500 000 € approx. EUR 71k in FY2020
Slide 15: Rights Issue 2021
Rights Issue 2021 Financials More information about the Offering including the Prospectus available at www.nexstim.com/investors/rights- issue-2021/ Nexstim Plc Public Presentation 15
Slide 16: Key Strategic Objectives for Year 2021
Key Strategic Objectives for Year 2021 Business Operations 1 Focus on achieving profitable revenue growth and strict management of operating expenses Report first results from the two new pilot studies in treating severe depression and/or chronic pain patients with accelerated 2 therapy treatment pr
Slide 17: Nexstim has a unique proprietary neuronavigated TMS technology
Nexstim has a unique proprietary neuronavigated TMS technology that delivers best in class mapping and treatment for patients with brain diseases and disorders. We are well positioned to a disruptive shift in depression treatment and therapy delivery. With improving economics, driven by record reven
Slide 18: Thank you!
Thank you! Nexstim Plc Public Presentation 18
Nexstim — Nexstim Corporate Presentation Webinar 2021 on 6ix